Add to ORKGThis is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. Open Access Full open access to this and thousands of other papers a
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in...
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely appl...
Jong-Mi Lee,1 May H Han1,2 1Stanford Healthcare, Multiple Sclerosis Center, 2Department of Neurolog...
Abstract: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, ...
Clemens Warnke1,2, Olaf Stüve3,4, Hans-Peter Hartung1, Anna Fogdell-Hahn2, Bernd C Kieseier...
The Author(s) 2015. This article is published with open access at Springerlink.com Introduction: Fin...
Alberto Gajofatto,1,2 Marco Turatti,2 Salvatore Monaco,1,2 Maria Donata Benedetti2 1Department of Ne...
Fingolimod is a multiple sclerosis treatment licensed in Europe since 2011. Its efficacy has been de...
Fingolimod is a first in class oral compound approved for the treatment of relapsing-remitting multi...
WOS: 000419248500004Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous s...
The safety profile of fingolimod is well estab- lished in clinical trials and post-marketing studies...
Oral fingolimod has been recently accepted as a treatment for relapsing Multiple Sclerosis (MS) by t...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
none12nononeA. Laroni; D. Brogi; V. Brescia Morra; L. Guidi; C. Pozzilli; G. Comi; A. Lugaresi; R. T...
Background and Objectives: Multiple sclerosis (MS) is a disease that involves an individualchr('39')...
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in...
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely appl...
Jong-Mi Lee,1 May H Han1,2 1Stanford Healthcare, Multiple Sclerosis Center, 2Department of Neurolog...
Abstract: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, ...
Clemens Warnke1,2, Olaf Stüve3,4, Hans-Peter Hartung1, Anna Fogdell-Hahn2, Bernd C Kieseier...
The Author(s) 2015. This article is published with open access at Springerlink.com Introduction: Fin...
Alberto Gajofatto,1,2 Marco Turatti,2 Salvatore Monaco,1,2 Maria Donata Benedetti2 1Department of Ne...
Fingolimod is a multiple sclerosis treatment licensed in Europe since 2011. Its efficacy has been de...
Fingolimod is a first in class oral compound approved for the treatment of relapsing-remitting multi...
WOS: 000419248500004Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous s...
The safety profile of fingolimod is well estab- lished in clinical trials and post-marketing studies...
Oral fingolimod has been recently accepted as a treatment for relapsing Multiple Sclerosis (MS) by t...
© the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unre...
none12nononeA. Laroni; D. Brogi; V. Brescia Morra; L. Guidi; C. Pozzilli; G. Comi; A. Lugaresi; R. T...
Background and Objectives: Multiple sclerosis (MS) is a disease that involves an individualchr('39')...
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in...
Classical multiple sclerosis (MS) treatments using first-line injectable drugs, although widely appl...
Jong-Mi Lee,1 May H Han1,2 1Stanford Healthcare, Multiple Sclerosis Center, 2Department of Neurolog...